WO2025022354 - TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH A THERMALLY GELLING PHARMACEUTICAL COMPOSITION CONTAINING MITOMYCIN
National phase entry:
Publication Number
WO/2025/022354
Publication Date
30.01.2025
International Application No.
PCT/IB2024/057229
International Filing Date
25.07.2024
Title **
[English]
TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH A THERMALLY GELLING PHARMACEUTICAL COMPOSITION CONTAINING MITOMYCIN
[French]
TRAITEMENT DU CANCER DE LA VESSIE INVASIF NON MUSCULAIRE À RISQUE INTERMÉDIAIRE DE FAIBLE QUALITÉ AVEC UNE COMPOSITION PHARMACEUTIQUE THERMOGÉLIFIANTE CONTENANT DE LA MITOMYCINE
Applicants **
UROGEN PHARMA LTD.
Inventors
RAJU, Sunil
Priority Data
63/515,352
25.07.2023
US
63/640,252
30.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2297 | |
| EPO | Filing, Examination, Granting | 9294 | |
| Japan | Filing, Examination, Granting | 2062 | |
| South Korea | Filing, Examination, Granting | 1916 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,309
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
A method of reducing risk of bladder tumor recurrence, progression or death, or a method of increasing probability of disease-free survival at 15 months post-treatment, or a method of increasing probability of maintaining an achieved complete response for at least 15 months post-treatment comprises administering to a patient in need thereof a thermally gelling pharmaceutical composition once weekly for six weeks, the patient having low-grade intermediate-risk non-muscle invasive bladder cancer, and the thermally gelling pharmaceutical composition comprising a reverse thermal gelation agent, a polymer, and mitomycin. The risk is reduced or the probability is increased in comparison to the risk or probability expected if the patient were instead to receive TURBT monotherapy as treatment.[French]
Un procédé de réduction du risque de récidive, de progression ou de mort de tumeur de la vessie, ou un procédé d'augmentation de la probabilité de survie sans maladie à 15 mois après traitement, ou un procédé d'augmentation de la probabilité de maintien d'une réponse complète atteinte pendant au moins 15 mois après traitement comprend l'administration à un patient qui en a besoin d'une composition pharmaceutique thermogélifiante une fois hebdomadaire pendant six semaines, le patient ayant un cancer de la vessie invasif non musculaire à risque intermédiaire de faible qualité, et la composition pharmaceutique thermogélifiante comprenant un agent de gélification thermique inverse, un polymère et de la mitomycine. Le risque est réduit ou la probabilité est augmentée par rapport au risque ou à la probabilité attendu si le patient devait plutôt recevoir une monothérapie TURBT en tant que traitement.